Compare Pfizer Inc (PFE) vs Union Pacific Corporation (UNP) Price & Performance

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Union Pacific (UNP) trades at $288.45, down 0.4% on the day, with a bearish technical signal but strong fundamentals including a 28.85% net income margin and robust cash flow. Recent earnings beats in Q1 and Q2 2026, coupled with a pending Norfolk Southern merger expected to close by late 2027, highlight growth potential. The stock is supported by a consensus analyst price target of $334.33, indicating 16% upside.

The outlook is positive due to solid profitability and merger prospects, but risks include regulatory hurdles for the merger and economic sensitivity. Analysts are predominantly bullish (58.7% buy ratings), though technical indicators suggest near-term caution with support at $287.